Key Points
- MoonLake Immunotherapeutics CEO Da Silva Jorge Santos sold 33,936 shares on July 9 at an average price of $20.01, totaling about $679,059. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Santos also sold additional stock recently, including 68,289 shares on July 10 and 47,775 shares on July 1, indicating a broader pattern of insider selling in early July.
- The company’s shares were trading near $20.41, while analysts remain mixed: MoonLake has a Hold consensus rating and a consensus price target of $24.21, even as several firms maintain bullish targets.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 33,936 shares of the company's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $20.01, for a total value of $679,059.36. Following the completion of the transaction, the chief executive officer directly owned 2,843,182 shares in the company, valued at approximately $56,892,071.82. The trade was a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Da Silva Jorge Santos also recently made the following trade(s):
- On Friday, July 10th, Da Silva Jorge Santos sold 68,289 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $20.02, for a total value of $1,367,145.78.
- On Wednesday, July 1st, Da Silva Jorge Santos sold 47,775 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.03, for a total value of $956,933.25.
MoonLake Immunotherapeutics Price Performance
Shares of NASDAQ:MLTX opened at $20.41 on Tuesday. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39. The company has a market cap of $1.50 billion, a PE ratio of -5.27 and a beta of 1.04. The company's 50 day moving average is $18.68 and its 200 day moving average is $17.30.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.07). On average, sell-side analysts forecast that MoonLake Immunotherapeutics will post -3.71 EPS for the current year.
Wall Street Analyst Weigh In
MLTX has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, June 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and increased their target price for the stock from $12.00 to $40.00 in a research note on Thursday, March 19th. Wolfe Research upgraded MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and lifted their price target for the company from $12.00 to $24.00 in a research note on Monday, March 23rd. Finally, Leerink Partners increased their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of "Hold" and a consensus price target of $24.21.
Read Our Latest Stock Report on MLTX
Institutional Trading of MoonLake Immunotherapeutics
Large investors have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new position in MoonLake Immunotherapeutics in the 4th quarter valued at $26,000. EverSource Wealth Advisors LLC raised its position in shares of MoonLake Immunotherapeutics by 221.1% in the first quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company's stock valued at $53,000 after buying an additional 1,974 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of MoonLake Immunotherapeutics in the second quarter worth about $58,000. Russell Investments Group Ltd. boosted its position in MoonLake Immunotherapeutics by 45.4% during the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock worth $45,000 after acquiring an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in MoonLake Immunotherapeutics during the 4th quarter valued at about $47,000. 93.85% of the stock is currently owned by hedge funds and other institutional investors.
MoonLake Immunotherapeutics Company Profile
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
